| Literature DB >> 15856047 |
Yasushi Takii1, Minoru Nakamura, Masahiro Ito, Terufumi Yokoyama, Atsumasa Komori, Yuki Shimizu-Yoshida, Rumiko Nakao, Koichiro Kusumoto, Shinya Nagaoka, Koji Yano, Seigo Abiru, Toshihito Ueki, Takehiro Matsumoto, Manabu Daikoku, Ken Taniguchi, Hikaru Fujioka, Kiyoshi Migita, Hiroshi Yatsuhashi, Masahiro Nakashima, Mine Harada, Hiromi Ishibashi.
Abstract
The pathogenesis of primary biliary cirrhosis (PBC) remains enigmatic. In order to address this issue, we analyzed by laser capture microdissection and real-time reverse transcription-polymerase chain reaction the site-specific expression of messenger RNA (mRNA) for cytokines (interferon (IFN)-alpha, -beta, -gamma, interleukin (IL)-1beta, -4, -6, -10, -12p40, -18, tumor necrosis factor-alpha) and toll-like receptors (TLRs) (TLR-2, -3, -4, -7, -9) in portal tract and liver parenchyma from patients with early-stage PBC. Expression of IFN-alpha, -beta and TLR-3 proteins was also studied by immunohistochemistry. Autoimmune hepatitis (AIH) and chronic hepatitis C (CHC) served as disease controls. The expression levels of type I IFN (IFN-alpha, -beta) and TLR-3 mRNAs, which are known to induce type I IFN, were significantly higher in portal tract and liver parenchyma as compared to AIH and CHC. A strong positive correlation between the mRNA levels of type I IFN and TLR-3 was also seen in both areas. Immunohistologically, IFN-alpha is present in the mononuclear cells in portal tract and sinusoidal cells. Macrophages in portal tract and hepatocytes expressed IFN-beta and TLR-3. Furthermore, the level of IFN-alpha mRNA in the portal tract was positively correlated with serum alkaline phosphatase. In conclusion, these data indicate that TLR-3 and type I IFN signaling pathways are active in both the portal tract and liver parenchyma of early-stage PBC, and form the basis for our hypothesis that these signaling pathways are involved in the pathophysiology of PBC.Entities:
Mesh:
Substances:
Year: 2005 PMID: 15856047 DOI: 10.1038/labinvest.3700285
Source DB: PubMed Journal: Lab Invest ISSN: 0023-6837 Impact factor: 5.662